Immunomedics Develops Potential New Treatment Regimen for Non-Hodgkin Lymphoma

Immunomedics

autoimmune and other serious diseases, today reported initial clinical experience with a combination of epratuzumab, the Company's humanized anti-CD22 antibody, labeled with the radioisotope, yttrium-90 (^90Y), and veltuzumab, the Company's humanized anti-CD20 antibody, in patients with relapsed aggressive non-Hodgkin lymphoma (NHL).